These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Design, synthesis and anticancer evaluation of new 4-anilinoquinoline-3-carbonitrile derivatives as dual EGFR/HER2 inhibitors and apoptosis inducers. Zou M; Li J; Jin B; Wang M; Chen H; Zhang Z; Zhang C; Zhao Z; Zheng L Bioorg Chem; 2021 Sep; 114():105200. PubMed ID: 34375195 [TBL] [Abstract][Full Text] [Related]
23. Synthesis and biological evaluation of novel xanthine derivatives as potential apoptotic antitumor agents. Hisham M; Youssif BGM; Osman EEA; Hayallah AM; Abdel-Aziz M Eur J Med Chem; 2019 Aug; 176():117-128. PubMed ID: 31108261 [TBL] [Abstract][Full Text] [Related]
24. Synthesis and Anticancer Activity of Novel Indole Derivatives as Dual EGFR/SRC Kinase Inhibitors. Olgen S; Kaleli SNB; Karaca BT; Demirel UU; Bristow HK Curr Med Chem; 2024; 31(24):3798-3817. PubMed ID: 37365789 [TBL] [Abstract][Full Text] [Related]
25. Design, synthesis, and antiproliferative activity of new indole/1,2,4-triazole/chalcone hybrids as EGFR and/or c-MET inhibitors. Mahmoud E; Abdelhamid D; Youssif BGM; Gomaa HAM; Hayallah AM; Abdel-Aziz M Arch Pharm (Weinheim); 2024 Sep; 357(9):e2300562. PubMed ID: 39219313 [TBL] [Abstract][Full Text] [Related]
28. Design and synthesis of novel 2,3-dihydropyrazino[1,2-a]indole-1,4-dione derivatives as antiproliferative EGFR and BRAF Al-Wahaibi LH; Gouda AM; Abou-Ghadir OF; Salem OIA; Ali AT; Farghaly HS; Abdelrahman MH; Trembleau L; Abdu-Allah HHM; Youssif BGM Bioorg Chem; 2020 Nov; 104():104260. PubMed ID: 32920363 [TBL] [Abstract][Full Text] [Related]
29. Novel sulphonamide benzoquinazolinones as dual EGFR/HER2 inhibitors, apoptosis inducers and radiosensitizers. Soliman AM; Alqahtani AS; Ghorab M J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1030-1040. PubMed ID: 31074303 [TBL] [Abstract][Full Text] [Related]
30. Design and synthesis of thienopyrimidine urea derivatives with potential cytotoxic and pro-apoptotic activity against breast cancer cell line MCF-7. Abdelhaleem EF; Abdelhameid MK; Kassab AE; Kandeel MM Eur J Med Chem; 2018 Jan; 143():1807-1825. PubMed ID: 29133058 [TBL] [Abstract][Full Text] [Related]
31. Novel pyrazolo[3,4-d]pyrimidines: design, synthesis, anticancer activity, dual EGFR/ErbB2 receptor tyrosine kinases inhibitory activity, effects on cell cycle profile and caspase-3-mediated apoptosis. Maher M; Kassab AE; Zaher AF; Mahmoud Z J Enzyme Inhib Med Chem; 2019 Dec; 34(1):532-546. PubMed ID: 30688116 [TBL] [Abstract][Full Text] [Related]
32. Design, Synthesis and Cytotoxic Evaluation of Novel Chalcone Derivatives Bearing Triazolo[4,3-a]-quinoxaline Moieties as Potent Anticancer Agents with Dual EGFR Kinase and Tubulin Polymerization Inhibitory Effects. Alswah M; Bayoumi AH; Elgamal K; Elmorsy A; Ihmaid S; Ahmed HEA Molecules; 2017 Dec; 23(1):. PubMed ID: 29280968 [TBL] [Abstract][Full Text] [Related]
33. Design, synthesis and biological evaluation of novel 4-anlinoquinazoline derivatives as EGFR inhibitors with the potential to inhibit the gefitinib-resistant nonsmall cell lung cancers. Wang C; Xu S; Peng L; Zhang B; Zhang H; Hu Y; Zheng P; Zhu W J Enzyme Inhib Med Chem; 2019 Dec; 34(1):203-217. PubMed ID: 30835140 [TBL] [Abstract][Full Text] [Related]
34. Design, synthesis and biological evaluation of a new series of thiazolyl-pyrazolines as dual EGFR and HER2 inhibitors. Sever B; Altıntop MD; Radwan MO; Özdemir A; Otsuka M; Fujita M; Ciftci HI Eur J Med Chem; 2019 Nov; 182():111648. PubMed ID: 31493743 [TBL] [Abstract][Full Text] [Related]
35. Design, synthesis, molecular docking and cytotoxic evaluation of novel 2-furybenzimidazoles as VEGFR-2 inhibitors. Abdullaziz MA; Abdel-Mohsen HT; El Kerdawy AM; Ragab FAF; Ali MM; Abu-Bakr SM; Girgis AS; El Diwani HI Eur J Med Chem; 2017 Aug; 136():315-329. PubMed ID: 28505536 [TBL] [Abstract][Full Text] [Related]
36. Synthesis, anticancer effect and molecular modeling of new thiazolylpyrazolyl coumarin derivatives targeting VEGFR-2 kinase and inducing cell cycle arrest and apoptosis. Mohamed TK; Batran RZ; Elseginy SA; Ali MM; Mahmoud AE Bioorg Chem; 2019 Apr; 85():253-273. PubMed ID: 30641320 [TBL] [Abstract][Full Text] [Related]
37. New oxadiazoles with selective-COX-2 and EGFR dual inhibitory activity: Design, synthesis, cytotoxicity evaluation and in silico studies. El-Sayed NA; Nour MS; Salem MA; Arafa RK Eur J Med Chem; 2019 Dec; 183():111693. PubMed ID: 31539778 [TBL] [Abstract][Full Text] [Related]
38. Design, synthesis and molecular modeling studies of 2-styrylquinazoline derivatives as EGFR inhibitors and apoptosis inducers. Amin NH; Elsaadi MT; Zaki SS; Abdel-Rahman HM Bioorg Chem; 2020 Dec; 105():104358. PubMed ID: 33074119 [TBL] [Abstract][Full Text] [Related]
39. Molecular modelling and synthesis of quinazoline-based compounds as potential antiproliferative agents. Yassen AS; Elshihawy HE; Said MM; Abouzid KA Chem Pharm Bull (Tokyo); 2014; 62(5):454-66. PubMed ID: 24789927 [TBL] [Abstract][Full Text] [Related]
40. Eco-friendly synthesis of novel cyanopyridine derivatives and their anticancer and PIM-1 kinase inhibitory activities. Abouzid KAM; Al-Ansary GH; El-Naggar AM Eur J Med Chem; 2017 Jul; 134():357-365. PubMed ID: 28431341 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]